ProCE Banner Activity

Phase II ZUMA-1: Interim Analysis of Anti-CD19 CAR T-Cell Therapy in Patients With Refractory Aggressive DLBCL

Slideset Download
Conference Coverage
Interim analysis reported significantly higher ORR and markedly greater CR with KTE-C19 vs historical rates in chemorefractory patients with DLBCL.

Released: December 09, 2016

Expiration: December 08, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen